The EuMederis platform technology (EuPort) is directed at improvements in the bioavailability and duration of action of peptide therapeutics. This technology is designed to be effective for the administration of peptides by subcutaneous, intranasal and oral routes.

When used for subcutaneous administration, EuPort-modified products form a micellar/liquid crystal depot and then reversibly bind to serum albumin for extended circulation in the body (fully flexible for pharmacodynamic profiles lasting hours to days).

Transmucosal bioavailability is facilitated by the surfactant like character of the new chemical entity achieved by linkage to the EuPort modification.

The novelty and efficacy of our proprietary modifications allows broad entry into a wide range of intellectual property space for the resultant pharmaceutical candidates. International search reports support the complete novelty of the EuPort modification and broad international patent filings have been allowed.


Although there are many therapeutics that slow the loss of bone, only the parathyroid hormone (PTH)/parathyroid hormone-related peptide (PTHrP) family provides dramatic increases in bone density. Nonetheless, current use of PTH requires daily, long-term use of subcutaneous injections and may not be well-received by all patients. Similarly, in treatment of hypoparathyroidism, a smooth infusion-like pharmacokinetic profile is preferred for reduced side effects. Our EuPort-modified PTHrP analogs have such a profile as well as other advantages, such as for bioavailability.

EuMederis is investigating truncated analogs of PTH and PTHrP for their use as bone anabolic agents with improved bioavailability and function.

EuMederis has now shown proof of concept, both in cellular assays and in vivo, with Eu-232, a highly potent and long-acting analog of PTHrP for use with a modified route and timing of administration in osteoporosis patients and may have especially useful benefits in hypoparathyroidism through a lowered peak to trough ratio to minimize side effects.


Alleviation of pain remains one of the central challenges to physicians and many candidates have been investigated. Nonetheless, it remains an area with major unmet medical needs. Current treatment continues to rely on opiates, with their inherent side effects: respiratory depression, somnolence, tolerance, addiction potential, and constipation. We have analogs designed for peripheral-only function and more prolonged duration of action.

EuMederis is evaluating mu opioid receptor agonists that block pain, but which are restricted to the periphery, therefore without the potential for central side effects such as euphoria, respiratory depression, drowsiness, dependence and addiction.

EuMederis has now shown proof of concept, both in cellular assays and in vivo, with Eu-178, a highly potent analog of an endogenous opioid peptide, combining full mu receptor agonism with highly potent delta receptor antagonism. This profile is regarded as having the potential benefits of increased potency and reduced tolerance.


Obesity, and the resultant Metabolic Syndrome (insulin resistance, diabetes, hypertension, atherosclerosis), has become a worldwide epidemic and is responsible for one of the largest categories of healthcare costs in developed countries. Obesity results in a systemic inflammatory state that drives the downstream sequela. EuMederis is carrying out drug design work addressing multiple mechanisms involved in the development of the Metabolic Syndrome.

EuMederis has multiple projects directed at addressing this syndrome, both from the direction of feeding/satiety induction/metabolism increase and by addressing the inflammatory cytokine response.


The EuPorttechnology was the subject of a licensing agreement with Spitfire Pharma, Inc., a Velocity Pharmaceutical Development-backed drug development company operating in the diabetes space. This partnership resulted in a EuPort-modified, highly potent, GLP-1/glucagon dual receptor agonist (variously SP-1373/ALT-801/pemvidutide). EuMederis is seeking research partnerships outside of the incretin space. Spitfire was purchased by Altimmune, Inc. for pemvidutide and it now shows best-in-class potential in human clinical trials for obesity and NAFLD/NASH by once weekly SC administration. The late Tmax and low Cmax provided by the EuPort modification leads to a low peak to trough ratio and a reduced potential for side effects, resulting in a highly favorable product profile.

EuMederis Pharmaceuticals comes from the Latin and indicates our commitment to the identification of novel pharmaceuticals that represent important advances for patient health and well-being:

Eu = good, true

Mederis = to cure (future tense)

Breadth of Application

A number of additional projects are in the design and patent filing stages. If your company has an interest in peptide hormones, your project may already be in planning at EuMederis Pharmaceuticals. We encourage you to start the conversation about a target of interest to your company.

Call us for a discussion of how we can help you identify superior clinical candidates.